Introducing Marc Coenen as the Fiberguide European Account Manager

Fiberguide recently expanded our footprint to better serve our European customers. Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network. Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction.

Marc has a Master of Science degree in Information Technology from the University of Technology Eindhoven in the Netherlands. Prior to joining Fiberguide, he served as Sales Manager Automotive Europe, Area Sales Manager, and Application Engineer at Therm-O-Disc. While all of this experience is undoubtedly important, it’s his belief that “If people like you, they’ll listen to you, but if they trust you they’ll do business with you” that certainly sets Marc Coenen apart from the crowd. It is also in line with Fiberguide’s core values of innovative design, outstanding customer service and unparalleled quality.

“After 12 years at my former company, I was looking for a new challenge in a different field,” Marc explains. “A job where I could learn again, pioneer, and bring added value to the company. Fiberguide offered me that unique position to set up the European sales locally.”

Marc’s goal is to expand Fiberguide’s footprint on the European Fiber Optics map—he’ll be working to grow the Fiberguide business significantly by discovering new accounts and working with our EU partner AMS Technologies. “As distributors sell products from several suppliers, they need to know they will have the support and backing of their vendors,” Marc says. “In my role, I will support them in order to get the inquiries awarded and ensure they have the tools needed to succeed.”

If determination is the secret to success, Fiberguide is poised to enjoy a whole new era of growth in Europe thanks to our new European Account Manager’s focus and skills. If you’d like to connect with Marc to learn more about Fiberguide’s operations in Europe, give him a call at +316 1818 5008 or reach out to him at mcoenen@fiberguide.com.

Read more at fiberguide.com

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More